Abnormal skin barrier in the etiopathogenesis of atopic dermatitis

Current Allergy and Asthma Reports

Volumn 9, Issue 4, 2009, Pages 265-272

  Elias, Peter M ^a   Schmuth, Matthias ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; FILAGGRIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; KALLEKREIN RELATED PEPTIDASE 7; PEPTIDASE; PLASMINOGEN ACTIVATOR RECEPTOR 2; PROTEIN SPINK; SERINE PROTEINASE; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ALLERGIC REACTION; ATOPIC DERMATITIS; CYTOKINE PRODUCTION; DERMATOMYCOSIS; ENZYME ACTIVITY; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE LOCATION; HUMAN; INFLAMMATION; LAMELLAR BODY; LOSS OF FUNCTION MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; PATHOGENESIS; PERMEABILITY BARRIER; PHENOTYPE; PROTEIN DEFICIENCY; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STAPHYLOCOCCUS INFECTION; STRATUM CORNEUM; TH2 CELL; VIRUS INFECTION;

BACTERIA; CYTOKINES; DERMATITIS, ATOPIC; HUMANS; INTERMEDIATE FILAMENT PROTEINS; SKIN; TH2 CELLS;

EID: 68349089102     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-009-0037-y     Document Type: Review

References (68)

1. Sugarman JL, Fluhr JW, Fowler AJ, et al.: The objective severity assessment of atopic dermatitis score: An objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol 2003, 139: 1417-1422.
2. Seidenari S, Giusti G: Objective assessment of the skin of children affected by atopic dermatitis: A study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol 1995, 75: 429-433.
3. Proksch E, Folster-Holst R, Jensen JM: Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci 2006, 43: 159-169.
4. Chamlin SL, Kao J, Frieden IJ, et al.: Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: Changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002, 47: 198-208.
5. Baker BS: The role of microorganisms in atopic dermatitis. Clin Exp Immunol 2006, 144: 1-9.
6. Elias PM, Wood LC, Feingold KR: Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat 1999, 10: 119-126.
7. Elias PM, Feingold KR: Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol 2001, 137: 1079-1081.
8. Taieb F: Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact Dermatitis 1999, 41: 177-180.
9. Grimalt R, Mengeaud V, Cambazard F: The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: A randomized controlled study. Dermatology 2007, 214: 61-67.
10. Elias PM: Stratum corneum defenAive functions: an integrated view. J Invest Dermatol 2005, 125: 183-200.
11. Elias PM: The skin barrier as an innate immune element. Semin Immunopathol 2007, 29: 3-14.
12. Caubet C, Jonca N, Brattsand M, et al.: Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol 2004, 122: 1235-1244.
13. Brattsand M, Stefansson K, Lundh C, et al.: A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol 2005, 124: 198-203.
14. Braff MH, Di Nardo A, Gallo RL: Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol 2005, 124: 394-400.
15. Oren A, Ganz T, Liu L, Meerloo T: In human epidermis, beta-defensin 2 is packaged in lamellar bodies. Exp Mol Pathol 2003, 74: 180-182.
16. Walley AJ, Chavanas S, Moffatt MF, et al.: Gene polymorphism in Netherton and common atopic disease. Nat Genet 2001, 29: 175-178.
17. Hachem JP, Wagberg F, Schmuth M, et al.: Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol 2006, 126: 1609-1621.
18. Vasilopoulos Y, Cork MJ, Murphy R, et al.: Genetic association between an AACC insertion in the 3 - UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J Invest Dermatol 2004, 123: 62-66.
19. Hubiche T, Ged C, Benard A, et al.: Analysis of SPINK 5, KLK 7 and FLG genotypes in a french atopic dermatitis cohort. Acta Derm Venereol 2007, 87: 499-505.
20. Folster-Holst R, Stoll M, Koch WA, et al.: Lack of association of SPINK5 polymorphisms with nonsyndromic atopic dermatitis in the population of Northern Germany. Br J Dermatol 2005, 152: 1365-1367.
21. Weidinger S, Baurecht H, Wagenpfeil S, et al.: Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk. J Allergy Clin Immunol 2008, 122: 560-568.e4.
22. Hachem JP, Crumrine D, Fluhr J, et al.: PH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/ cohesion. J Invest Dermatol 2003, 121: 345-353.
23. Di Nardo A, Wertz P, Giannetti A, Seidenari S: Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 1998, 78: 27-30.
24. Imokawa G, Abe A, Jin K, et al.: Decreased level of ceramides in stratum corneum of atopic dermatitis: An etiologic factor in atopic dry skin? J Invest Dermatol 1991, 96: 523-526.
25. Hachem JP, Houben E, Crumrine D, et al.: Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol 2006, 126: 2074-2086.
26. Sator PG, Schmidt JB, Honigsmann H: Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J Am Acad Dermatol 2003, 48: 352-358.
27. Irvine AD, McLean WH: BreaFing the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Invest Dermatol 2006, 126: 1200-1202.
28. Hudson TJ: Skin barrier function and allergic risk. Nat Genet 2006, 38: 399-400.
29. Fleckman P, Brumbaugh S: Absence of the granular layer and keratohyalin define a morphologically distinct subset of individuals with ichthyosis vulgaris. Exp Dermatol 2002, 11: 327-336.
30. Howell MD, Kim BE, Gao P, et al.: Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007, 120: 150-155.
31. Bieber T: Atopic dermatitis. N Engl J Med 2008, 358: 1483-1494.
32. O'Regan GM, Sandilands A, McLean WH, Irvine AD: Filaggrin in atopic dermatitis. J Allergy Clin Immunol 2008, 122: 689-693.
33. Sandilands A, Smith FJ, Irvine AD, McLean WH: Filaggrin's fuller figure: a glimpse into the genetic architecture of atopic dermatitis. J Invest Dermatol 2007, 127: 1282-1284.
34. Lynley AM, Dale BA: The characterization of human epidermal filaggrin. A histidine-rich, keratin filament-aggregating protein. Biochim Biophys Acta 1983, 744: 28-35.
35. Harding CR, Scott IR: Histidine-Sich proteins (filaggrins): structural and functional heterogeneity during epidermal differentiation. J Mol Biol 1983, 170: 651-673.
36. Fleckman P, Dale BA, Holbrook KA: Profilaggrin, a high-molecular-weight precursor of filaggrin in human epidermis and cultured keratinocytes. J Invest Dermatol 1985, 85: 507-512.
37. Takahashi M, Tezuka T, Katunuma N: Filaggrin linker segment peptide and cystatin alpha are parts of a complex of the cornified envelope of epidermis. Arch Biochem Biophys 1996, 329: 123-126.
38. Steinert PM, Marekov LN: The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope. J Biol Chem 1995, 270: 17702-17711.
39. Scott IR, Harding CR, Barrett JG: Histidine-rich protein of the keratohyalin granules. Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. Biochim Biophys Acta 1982, 719: 110-117.
40. Rawlings AV, Scott IR, Harding CR, Bowser PA: Stratum corneum moisturization at the molecular level. J Invest Dermatol 1994, 103: 731-741.
41. Abe T, Ohkido M, Yamamoto K: Studies on skin surface barrier functions: skin surface lipids and transepidermal water loss in atopic skin during childhood. J Dermatol 1978, 5: 223-229.
42. Werner Y, Lindberg M: Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol 1985, 65: 102-105.
43. Fartasch M, Diepgen TL: The barrier function in atopic dry skin. Disturbance of membrane-coating granule exocytosis and formation of epidermal lipids? Acta Derm Venereol Suppl (Stockh) 1992, 176: 26-31.
44. Scott IR, Harding CR: Filaggrin breakdown to water binding compounds during development of the rat stratum corneum is controlled by the water activity of the environment. Dev Biol 1986, 115: 84-92.
45. Krien P, Kermici M: Evidence for the existence of a self-regulated enzymatic process within human stratum corneum-an unexpected role for urocanic acid. J Invest Dermatol 2000, 115: 414-420.
46. Nylander-Lundqvist E, Back O, Egelrud T: IL-1 beta activation in human epidermis. J Immunol 1996, 157: 1699-1704.
47. Bisgaard H, Simpson A, Palmer CN, et al.: Gene-environment interaction in the onset of eczema in infancy: Filaggrin loss-of-function mutations enhanced by neonatal cat exposure. PLoS Med 2008, 5: E131.
48. Jeong SK, Kim HJ, Youm JK, et al.: Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery. J Invest Dermatol 2008, 128: 1930-1939.
49. Novak N, Baurecht H, Schafer T, et al.: Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel. J Invest Dermatol 2008, 128: 1430-1435.
50. Schlievert PM, Case LC, Strandberg KL, et al.: Superantigen profile of Staphylococcus aureus isolates from patients with steroid-resistant atopic dermatitis. Clin Infect Dis 2008, 46: 1562-1567.
51. Aberg KM, Man MQ, Gallo RL, et al.: Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. J Invest Dermatol 2008, 128: 917-925.
52. Cork MJ, Robinson DA, Vasilopoulos Y, et al.: New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions. J Allergy Clin Immunol 2006, 118: 3-21; quiz 22-23.
53. Garg A, Chren MM, Sands LP, et al.: Psychological stress perturbs epidermal permeability barrier homeostasis: Implications for the pathogenesis of stress-associated skin disorders. Arch Dermatol 2001, 137: 53-59.
54. Kurahashi R, Hatano Y, Katagiri K: IL-4 suppresses the recovery of cutaneous permeability barrier functions in vivo. J Invest Dermatol 2008, 128: 1329-1331.
55. Altrichter S, Kriehuber E, Moser J, et al.: Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis. J Invest Dermatol 2008, 128: 2232-2239.
56. Ong PY, Ohtake T, Brandt C, et al.: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002, 347: 1151-1160.
57. Miller SJ, Aly R, Shinefeld HR, Elias PM: In vitro and in vivo antistaphylococcal activity of human stratum corneum lipids. Arch Dermatol 1988, 124: 209-215.
58. Bibel DJ, Aly R, Shinefield HR: Antimicrobial activity of sphingosines. J Invest Dermatol 1992, 98: 269-273.
59. Nomura I, Goleva E, Howell MD, et al.: Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003, 171: 3262-3269.
60. Lomholt H, Andersen KE, Kilian M: Staphylococcus aureus clonal dynamics and virulence factors in children with atopic dermatitis. J Invest Dermatol 2005, 125: 977-982.
61. Wehner J, Neuber K: Staphylococcus aureus enterotoxins induce histamine and leukotriene release in patients with atopic eczema. Br J Dermatol 2001, 145: 302-305.
62. Leung DY, Harbeck R, Bina P, et al.: Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 1993, 92: 1374-1380.
63. SAnkoly E, Muller A, Lauerma AI, et al.: IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006, 117: 411-417.
64. Mazereeuw-Hautier J, Cope J, Ong C, et al.: Topical recombinant alpha1-antitrypsin: A potential treatment for Netherton syndrome ? Arch Dermatol 2006, 142: 396-398.
65. Sugarman J, Parish LJ: A topical lipid-based barrier repair formulation (EpiCeram cream) is high-effective monotherapy for moderate-to-severe pediatric atopic dermatitis. Presented at the IID Meeting 2008. Kyoto, Japan; May 14-17, 2008.
66. Galli SJ, Tsai M, Piliponsky AM: The development of allergic inflammation. Nature 2008, 454: 445-454.
67. De Benedetto A, Qualia CM, Baroody FM, Beck LA: Filaggrin expression in oral, nasal, and esophageal mucosa. J Invest Dermatol 2008, 128: 1594-1597.
68. Elias PM, Hatano Y, Williams ML: Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008, 121: 1337-1343.